Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

5902 - EUMelaReg - a European platform for outcome research on real world treatment data of patients with advanced melanoma.

Date

21 Oct 2018

Session

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

Topics

Cancer Prevention

Tumour Site

Melanoma

Presenters

Michael Weichenthal

Citation

Annals of Oncology (2018) 29 (suppl_8): viii442-viii466. 10.1093/annonc/mdy289

Authors

M. Weichenthal1, A.C.J. van Akkooi2, P. Mohr3, E. Ellebaek4, I. Svane4, S. Ugurel-Becker5, U. Leiter6, L. Hoejberg7, J.B.A.G. Haanen8, H. Schmidt9, T.H. Oellegaard10, M.W.J.M. Wouters2, D. Schadendorf11, L. Bastholt12

Author affiliations

  • 1 Dermatology, University of Kiel, 24105 - Kiel/DE
  • 2 Surgical oncology, The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, 1066 CX - Amsterdam/NL
  • 3 Skin Cancer Center, Dermatologic Center Buxtehude, 21614 - Buxtehude/DE
  • 4 Department Of Oncology, Herlev and Gentofte Hospital, 2730 - Herlev/DK
  • 5 Dermatology, University Hospital Essen, 45122 - Essen/DE
  • 6 Dermatooncology, Center for Dermatooncology, Department of Dermatology, University Hospital Tuebingen, 72016 - Tuebingen/DE
  • 7 Oncology, Odense University Hospital, 5000 - Odense C/DK
  • 8 Medical Oncology, The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, 1066 CX - Amsterdam/NL
  • 9 Department Of Oncology, Aarhus University Hospital, 8000 - Aarhus C/DK
  • 10 Oncology, Aarhus University Hospital, Aarhus C/DK
  • 11 Department Of Dermatology - Hautklinik, University Hospital Essen Westdeutsches Tumorzentrum, 45122 - Essen/DE
  • 12 Medical Oncology, Odense University Hospital, 5000 - Odense C/DK
More

Resources

Abstract 5902

Background

During the past ten years several fundamental breakthroughs have radically changed the treatment options in metastatic melanoma. Both targeted therapies (TT) and immunotherapies (IT) randomized clinical trials have shown significant benefit in relapse free and overall survival. Since the underlying clinical trials represent selected patient populations who had to meet several inclusion and exclusion criteria, the EuMelaReg consortium sought to evaluate "real world" melanoma cases presenting for initial treatment decision with stage IV or unresectable stage III disease.

Methods

Data sources from Denmark (Danish metastatic melanoma database), Germany (ADOReg Registry) or The Netherlands (Dutch Melanoma Treatment Registry) were merged in a stepwise procedure into a standardized data representation format. The harmonized database for the current analysis included subgroups of patients presenting in 2014 for treatment of non-resectable stage III or metastatic stage IV disease on a regular basis. Criteria used to validate the process of data harmonization contained primary demographic data as well as data concerning the advanced disease status (ECOG status, serum LDH, and baseline tumor burden including the presence of brain metastasis), and the different treatment strategies and regimens.

Results

It could be shown that more than 30 percent of the cases included would not have qualified for common inclusion and/or exclusion criteria of clinical phase III trials in advanced melanoma. Moreover, the distribution of prognostic and predicive factors varied substancially between the real-world populations and published study populations.

Conclusions

Final endpoints of the ongoing data collection and analysis will contain among other parameters progression free survival, overall survival, and tolerability of treatment. Collaboration is sought to a range of other European registries and countries.

Clinical trial identification

Legal entity responsible for the study

The EUMelaReg Consortium (European Melanoma Registries Network).

Funding

BMS, MSD, Roche, Novartis.

Editorial Acknowledgement

Disclosure

M. Weichenthal: Grants, honoraria, fees: BMS, MSD, Roche, Novartis, Millennium, Medac, Takeda, Amgen, Pierre-Fabre. A.C.J. van Akkooi, P. Mohr, E. Ellebaek, I-M. Svane, S. Ugurel-Becker, U. Leiter, L. Hoejberg, J.B.A.G. Haanen, H. Schmidt, T.H. Oellegaard, M.W.J.M. Wouters, D. Schadendorf, L. Bastholt: BMS, MSD, Roche, Novartis.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.